These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 33185469)

  • 21. Hydroxyurea for sickle-cell anaemia in Africa: mind the gap.
    Obaro SK
    Lancet Glob Health; 2015 Mar; 3(3):e124-5. PubMed ID: 25701988
    [No Abstract]   [Full Text] [Related]  

  • 22. [Treatment with hydroxyurea has revolutionized the evolution of sickle cell disease ].
    Bartolucci P; de Montalembert M
    Rev Prat; 2014 Oct; 64(8):1127-8. PubMed ID: 25510141
    [No Abstract]   [Full Text] [Related]  

  • 23. Experts urge wider use of hydroxyurea for sickle cell disease.
    Traynor K
    Am J Health Syst Pharm; 2008 Apr; 65(7):592-3. PubMed ID: 18359960
    [No Abstract]   [Full Text] [Related]  

  • 24. Hydroxyurea use among children with sickle cell anemia.
    Reeves SL; Jary HK; Gondhi JP; Raphael JL; Lisabeth LD; Dombkowski KJ
    Pediatr Blood Cancer; 2019 Jun; 66(6):e27721. PubMed ID: 30900800
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hydroxyurea and new agents for the treatment of sickle cell disease.
    Rodgers GP
    Clin Adv Hematol Oncol; 2004 Nov; 2(11):713-5. PubMed ID: 16163257
    [No Abstract]   [Full Text] [Related]  

  • 26. Hydroxyurea and sickle cell disease: a chance for every patient.
    Weiner DL; Brugnara C
    JAMA; 2003 Apr; 289(13):1692-4. PubMed ID: 12672739
    [No Abstract]   [Full Text] [Related]  

  • 27. Long-term use of hydroxyurea for sickle cell anemia.
    Feldman L; Allen S; Westerman M; Feldman L; Gilman-Sachs A; Beaman K
    JAMA; 2003 Aug; 290(6):752-3; author reply 754. PubMed ID: 12915423
    [No Abstract]   [Full Text] [Related]  

  • 28. Sickle cell patients find a brand New World.
    Noonan SS
    N J Med; 1999 Aug; 96(8):23-5. PubMed ID: 10457727
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Phase 3 Trial of l-Glutamine in Sickle Cell Disease.
    Niihara Y; Miller ST; Kanter J; Lanzkron S; Smith WR; Hsu LL; Gordeuk VR; Viswanathan K; Sarnaik S; Osunkwo I; Guillaume E; Sadanandan S; Sieger L; Lasky JL; Panosyan EH; Blake OA; New TN; Bellevue R; Tran LT; Razon RL; Stark CW; Neumayr LD; Vichinsky EP;
    N Engl J Med; 2018 Jul; 379(3):226-235. PubMed ID: 30021096
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hematology clinic. Sickle cell disease.
    Ngo D; Steinberg M
    Hematology; 2014 Jun; 19(4):244-5. PubMed ID: 24666152
    [No Abstract]   [Full Text] [Related]  

  • 31. The association of oral hydroxyurea therapy with improved cognitive functioning in sickle cell disease.
    Puffer E; Schatz J; Roberts CW
    Child Neuropsychol; 2007 Mar; 13(2):142-54. PubMed ID: 17364571
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sickle cell pain crisis.
    Davies SC; Bevan DH
    Lancet; 1996 Jan; 347(8996):263. PubMed ID: 8551907
    [No Abstract]   [Full Text] [Related]  

  • 33. Hydroxyurea Initiation Among Children With Sickle Cell Anemia.
    Reeves SL; Jary HK; Gondhi JP; Raphael JL; Lisabeth LD; Dombkowski KJ
    Clin Pediatr (Phila); 2019 Nov; 58(13):1394-1400. PubMed ID: 31113236
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hydroxyurea use in patients with sickle cell disease in a Medicaid population.
    Ritho J; Liu H; Hartzema AG; Lottenberg R
    Am J Hematol; 2011 Oct; 86(10):888-90. PubMed ID: 21922530
    [No Abstract]   [Full Text] [Related]  

  • 35. [Two splenic sequestrations in an infant with homozygous sickle cell anemia].
    Cueto González AM; Díaz Conradi A; Fábrega Sabaté J; Mate García MA; Solé Heuberger E; Villalba Hernández T; Tobeña Boada L
    An Pediatr (Barc); 2007 Mar; 66(3):322-3. PubMed ID: 17349264
    [No Abstract]   [Full Text] [Related]  

  • 36. Clinical complications in severe pediatric sickle cell disease and the impact of hydroxyurea.
    Tripathi A; Jerrell JM; Stallworth JR
    Pediatr Blood Cancer; 2011 Jan; 56(1):90-4. PubMed ID: 20922765
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MRI abnormalities in infants with sickle cell anemia-indication for preemptive therapy?
    Ozsahin H
    Pediatr Blood Cancer; 2008 Nov; 51(5):573-4. PubMed ID: 18623220
    [No Abstract]   [Full Text] [Related]  

  • 38. Hydroxyurea, sickle cell disease and renal transplantation.
    Allen A; Scoble J; Snowden S; Hambley H; Bellingham A
    Nephron; 1997; 75(1):106-7. PubMed ID: 9031282
    [No Abstract]   [Full Text] [Related]  

  • 39. European register of patients with sickle cell disease treated with hydroxyurea is being set up.
    Davies SC; Roberts-Harwood M
    BMJ; 1998 Aug; 317(7157):541-2. PubMed ID: 9712619
    [No Abstract]   [Full Text] [Related]  

  • 40. National Institutes of Health Consensus Development Conference statement: hydroxyurea treatment for sickle cell disease.
    Brawley OW; Cornelius LJ; Edwards LR; Gamble VN; Green BL; Inturrisi C; James AH; Laraque D; Mendez M; Montoya CJ; Pollock BH; Robinson L; Scholnik AP; Schori M
    Ann Intern Med; 2008 Jun; 148(12):932-8. PubMed ID: 18458271
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.